Satellos Bioscience Inc. (NASDAQ:MSLE) Receives Consensus Recommendation of “Hold” from Analysts

Satellos Bioscience Inc. (NASDAQ:MSLE) has been assigned an average rating of “Hold” from the five ratings firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $15.50.

Several research firms recently issued reports on MSLE. Zacks Research upgraded Satellos Bioscience to a “hold” rating in a report on Tuesday, February 10th. Leerink Partners assumed coverage on Satellos Bioscience in a research report on Monday. They issued an “outperform” rating and a $20.00 target price for the company. Weiss Ratings initiated coverage on shares of Satellos Bioscience in a research note on Wednesday, February 11th. They set a “sell (d-)” rating on the stock. HC Wainwright increased their price target on shares of Satellos Bioscience to $11.00 and gave the stock a “buy” rating in a research report on Monday, March 30th. Finally, Cantor Fitzgerald began coverage on shares of Satellos Bioscience in a research note on Wednesday, March 11th. They issued an “overweight” rating for the company.

Satellos Bioscience Trading Up 2.1%

Shares of NASDAQ MSLE traded up $0.13 during mid-day trading on Monday, reaching $6.00. 8,352 shares of the company’s stock were exchanged, compared to its average volume of 67,450. The stock has a market cap of $92.70 million, a PE ratio of -3.87 and a beta of 1.37. Satellos Bioscience has a 52-week low of $4.53 and a 52-week high of $13.39.

Satellos Bioscience (NASDAQ:MSLE) last issued its quarterly earnings data on Friday, March 27th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.11).

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.